Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...